ClinicalTrials.gg
CompletedNCT02819232KeratiteUpdated Apr 21, 2023

Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs

An interventional study of Blood sampling in Infectious Keratitis, sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Aug 2013, registered Jun 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
442
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Infectious keratitis are favored by the circumstances causing the small trauma of the corneal epithelium, corneal surgery, corneal dryness under health system such as Sjögren's syndrome rheumatoid arthritis, or much more frequently wearing contact lenses. If the majority of infectious keratitis are favourable, some lead to serious injury of the cornea, or even corneal perforation which result an endophthalmitis. This unfavourable evolution may lead to blindness due to corneal damage, the endo-ocular lesions or enucleation of the eyeball. This negative evolution is encountered while the infectious keratitis due to tedious germs of difficult diagnosis such as nontuberculous Mycobacterial, fungal infections, fungal keratitis, amoebic keratitis, and certain viral keratitis. The microbiological diagnosis of routine is based on the systematic search for pathogens tedious from invasive sampling of cornea by vaccinostyle. We set up a new non-invasive corneal swab diagnostic method.

Read the detailed description

Primary Purpose: Compare the ability diagnostic of non-invasive sampling swab corneal versus the gold standard, (invasive vaccinostyle uptake) for the systematic search for pathogens tedious in corneal specimens.

Hypothesis:

The diagnostic strategy using a microbial testing of cornea method has a sensitivity of 90% and a specificity of 80% or more over the policy diagnostic using a sampling by vaccinostyle method.

Primary outcome measures: Sensitivity, specificity, positive and negative predictive values, Diagnostic odds ratio.

02

Conditions studied

  • Infectious Keratitis

Browse trials for

03

In context

Keratitis

108 studies on the registry are indexed under Keratitis; 19 are open to participants now.

This study's enrollment of 442 is above the median of 40 across 70 interventional studies indexed under Keratitis.

Browse Keratitis studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is more than 18 years old.
  • Patient with a prescription of a microbiologic diagnostic of keratitis
  • Patient who do not declined to have his medical records reviewed for research
  • Patient with health insurance

Exclusion criteria

Exclusion Criteria:

  • minor patient (\<18 years).
  • Pregnant or breastfeeding women.
  • Major Patient under guardianship.
  • Patient in vital emergency.
  • Private Patient liberty or under court order.
  • Patient refusing to sign the form
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
442 participants (actual)

Study arms

  • Other
    Patient with a prescription of a microbiologic diagnostic of

    Patient with a prescription of a microbiologic diagnostic of keratitis

    Other: Blood sampling

Interventions

  • OtherBlood sampling

    Detection of bacteria will be performed on a blood sample

06

What researchers measure

Primary outcomes

  1. Sensitivity, specificity, positive and negative predictive values, Diagnostic odds ratio.

    Time frame: 1 day

07

Study locations

1 site
  • Assistance Publique Hopitaux de Marseille
    Marseille, 13354, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02819232
Responsible party
Sponsor
First posted
Jun 30, 2016
Start date
Aug 12, 2013
Primary completion
Mar 6, 2019
Completion
Oct 26, 2022
Last update
Apr 21, 2023

Study contacts

Michel Drancourt, Pr
principal investigator · Assistance Publique - Hôpitaux de Marseille

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion